

# Eduardo Collantes Estévez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6055322/publications.pdf>

Version: 2024-02-01

245  
papers

11,314  
citations

53794

45  
h-index

30922

102  
g-index

260  
all docs

260  
docs citations

260  
times ranked

8378  
citing authors

#	ARTICLE	IF	CITATIONS
1	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 777-783.	0.9	2,713
2	2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 896-904.	0.9	831
3	The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 770-776.	0.9	731
4	ASAS/EULAR recommendations for the management of ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 442-452.	0.9	571
5	New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 784-788.	0.9	498
6	Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 6-16.	0.9	397
7	Aqueous Humor and Serum Tumor Necrosis Factor- $\alpha$ in Clinical Uveitis. <i>Ophthalmic Research</i> , 2001, 33, 251-255.	1.9	287
8	Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1016-1023.	0.9	188
9	Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. <i>Rheumatology</i> , 2007, 46, 1309-1315.	1.9	160
10	A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1957-1962.	0.9	159
11	Predicting the outcome of ankylosing spondylitis therapy. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 973-981.	0.9	158
12	Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNF- $\alpha$ . <i>Arthritis Research and Therapy</i> , 2015, 17, 49.	3.5	158
13	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. <i>Arthritis and Rheumatology</i> , 2019, 71, 599-611.	5.6	142
14	Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. <i>Current Medical Research and Opinion</i> , 2004, 20, 155-157.	1.9	114
15	Anakinra: New therapeutic approach in children with Familial Mediterranean Fever resistant to colchicine. <i>Joint Bone Spine</i> , 2008, 75, 504-505.	1.6	114
16	Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E Initiative in Rheumatology involving a broad panel of experts and practising rheumatologists. <i>Rheumatology</i> , 2008, 47, 355-361.	1.9	96
17	Neutrophils: Novel key players in Rheumatoid Arthritis. <i>Current and future therapeutic targets. Autoimmunity Reviews</i> , 2018, 17, 1138-1149.	5.8	88
18	Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 675-682.	0.9	82

#	ARTICLE	IF	CITATIONS
19	Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q10 treatment. <i>Blood</i> , 2012, 119, 5859-5870.	1.4	82
20	Diagnostic potential of NETosis-derived products for disease activity, atherosclerosis and therapeutic effectiveness in Rheumatoid Arthritis patients. <i>Journal of Autoimmunity</i> , 2017, 82, 31-40.	6.5	82
21	Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases. <i>Arthritis and Rheumatology</i> , 2021, 73, 1073-1085.	5.6	81
22	Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. <i>Translational Research</i> , 2017, 183, 87-103.	5.0	80
23	First signs and symptoms of spondyloarthritis--data from an inception cohort with a disease course of two years or less (REGISPONER-Early). <i>Rheumatology</i> , 2009, 48, 404-409.	1.9	77
24	Differential Features Between Primary Ankylosing Spondylitis and Spondylitis Associated with Psoriasis and Inflammatory Bowel Disease. <i>Journal of Rheumatology</i> , 2011, 38, 1656-1660.	2.0	77
25	Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1441-1449.	0.9	76
26	Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. <i>Medicine (United States)</i> , 2016, 95, e5652.	1.0	72
27	Hip disease in ankylosing spondylitis. <i>Current Opinion in Rheumatology</i> , 2013, 25, 448-454.	4.3	69
28	Can some cases of "possible" spondyloarthropathy be classified as "definite" or "undifferentiated" spondyloarthropathy? Value of criteria for spondyloarthropathies. <i>Joint Bone Spine</i> , 2000, 67, 516-520.	1.6	63
29	Influence of HLA-B27 on the Ankylosing Spondylitis phenotype: results from the REGISPONER database. <i>Arthritis Research and Therapy</i> , 2018, 20, 221.	3.5	62
30	Ubiquinol Effects on Antiphospholipid Syndrome Prothrombotic Profile. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1923-1932.	2.4	60
31	Oxidative stress in the pathogenesis of atherothrombosis associated with anti-phospholipid syndrome and systemic lupus erythematosus: new therapeutic approaches. <i>Rheumatology</i> , 2016, 55, 2096-2108.	1.9	59
32	Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients. <i>Human Molecular Genetics</i> , 2018, 27, 875-890.	2.9	58
33	Prevalence of Vertebral Fractures by Semiautomated Morphometry in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 893-897.	2.0	57
34	Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. <i>Rheumatology</i> , 2005, 44, 1132-1135.	1.9	55
35	Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1034-1042.	0.9	53
36	Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2010, 62, 869-877.	6.7	52

#	ARTICLE	IF	CITATIONS
37	Anticyclic Citrullinated Protein Antibodies Are Implicated in the Development of Cardiovascular Disease in Rheumatoid Arthritis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 2706-2716.	2.4	52
38	Assessment of 2 systems of spondyloarthritis diagnostic and classification criteria (Amor and Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Rheumatology, 1995, 22, 246-51.	2.0	52
39	Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain. <i>Current Medical Research and Opinion</i> , 2003, 19, 402-410.	1.9	51
40	Association of the KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1000-1006.	6.7	51
41	Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 1218-1221.	0.9	50
42	Fat overload aggravates oxidative stress in patients with the metabolic syndrome. <i>European Journal of Clinical Investigation</i> , 2008, 38, 510-515.	3.4	50
43	Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1450-1458.	0.9	49
44	Work Disability in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2009, 36, 2512-2516.	2.0	48
45	Contribution of polymorphisms in the apolipoprotein AI-CIII-AIV cluster to hyperlipidaemia in patients with gout. <i>Annals of the Rheumatic Diseases</i> , 2005, 64, 85-88.	0.9	46
46	Validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1350-1355.	0.9	46
47	Comparison of the Clinical Expression of Patients with Ankylosing Spondylitis from Europe and Latin America. <i>Journal of Rheumatology</i> , 2012, 39, 2315-2320.	2.0	44
48	â€Atherothrombosis-associated microRNAs in Antiphospholipid syndrome and Systemic Lupus Erythematosus patientsâ€™. <i>Scientific Reports</i> , 2016, 6, 31375.	3.3	44
49	An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2006, 65, 1620-1625.	0.9	43
50	Design and performance of a multi-centre randomised controlled trial and economic evaluation of joint tele-consultations [ISRCTN54264250]. <i>BMC Family Practice</i> , 2002, 3, 1.	2.9	42
51	Non-inferiority of dose reduction versus standard dosing of TNF-inhibitors in axial spondyloarthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 11.	3.5	42
52	Clinical Features of Late-onset Ankylosing Spondylitis: Comparison with Early-onset Disease. <i>Journal of Rheumatology</i> , 2012, 39, 1008-1012.	2.0	40
53	High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). <i>Rheumatology</i> , 2011, 50, 1828-1837.	1.9	38
54	Evaluation of quality of life in patients with axial spondyloarthritis and its association with disease activity, functionality, mobility, and structural damage. <i>Clinical Rheumatology</i> , 2018, 37, 1581-1588.	2.2	38

#	ARTICLE	IF	CITATIONS
55	The Burden of Ankylosing Spondylitis in Spain. <i>Value in Health</i> , 2008, 11, 408-415.	0.3	37
56	A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 827-830.	0.9	37
57	Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. <i>Rheumatology</i> , 2014, 53, 353-360.	1.9	35
58	Defective glucose and lipid metabolism in rheumatoid arthritis is determined by chronic inflammation in metabolic tissues. <i>Journal of Internal Medicine</i> , 2018, 284, 61-77.	6.0	34
59	Infliximab in refractory spondyloarthropathies: a multicentre 38 week open study. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 1239-1240.	0.9	32
60	COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e50-e50.	0.9	32
61	Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. <i>Joint Bone Spine</i> , 2007, 74, 254-258.	1.6	31
62	Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 782-788.	0.9	31
63	Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis. <i>Clinical Rheumatology</i> , 2011, 30, 691-695.	2.2	31
64	Dietary Alterations in Plasma Very Low Density Lipoprotein Levels Modify Renal Excretion of Urates in Hyperuricemic-Hypertriglyceridemic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 1188-1191.	3.6	31
65	The effect of infliximab on oxidative stress in chronic inflammatory joint disease. <i>Current Medical Research and Opinion</i> , 2007, 23, 1259-1267.	1.9	30
66	Assessment of spinal mobility in ankylosing spondylitis using a video-based motion capture system. <i>Manual Therapy</i> , 2012, 17, 422-426.	1.6	30
67	Circulating microRNAs as biomarkers of disease and typification of the atherothrombotic status in antiphospholipid syndrome. <i>Haematologica</i> , 2018, 103, 908-918.	3.5	30
68	New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches. <i>Frontiers in Immunology</i> , 2019, 10, 764.	4.8	30
69	Is Spinal Mobility in Patients With Spondylitis Determined By Age, Structural Damage, and Inflammation?. <i>Arthritis Care and Research</i> , 2015, 67, 74-79.	3.4	29
70	Anti-dsDNA Antibodies Increase the Cardiovascular Risk in Systemic Lupus Erythematosus Promoting a Distinctive Immune and Vascular Activation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2417-2430.	2.4	29
71	Assessment of the efficacy of joint lavage versus joint lavage plus corticoids in patients with osteoarthritis of the knee. <i>Current Medical Research and Opinion</i> , 2004, 20, 861-867.	1.9	25
72	Circulating antioxidant defences are decreased in healthy people after a high-fat meal. <i>British Journal of Nutrition</i> , 2008, 100, 312-316.	2.3	24

#	ARTICLE	IF	CITATIONS
73	ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. <i>ReumatologĀa ClĀnica</i> , 2014, 10, 204-209.	0.5	24
74	Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. <i>Rheumatology International</i> , 2017, 37, 1239-1248.	3.0	24
75	Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. <i>Rheumatology</i> , 2005, 44, 1555-1558.	1.9	23
76	Diferente expresiĀn clĀnica de los pacientes con espondilitis anquilosante segĀn el sexo en funciĀn del tiempo de evoluciĀn. Datos de REGISPONSER. <i>ReumatologĀa ClĀnica</i> , 2013, 9, 221-225.	0.5	23
77	Treatment adherence during the COVID-19 pandemic and the impact of confinement on disease activity and emotional status: A survey in 644 rheumatic patients. <i>Joint Bone Spine</i> , 2021, 88, 105085.	1.6	23
78	Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2017, 69, 150-155.	3.4	22
79	Atlas of axial spondyloarthritis in Spain 2017: Study design and population. <i>ReumatologĀa ClĀnica</i> , 2019, 15, 127-132.	0.5	22
80	Effects of Biological Therapies on Molecular Features of Rheumatoid Arthritis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9067.	4.1	22
81	First Acute Gout Attacks Commonly Precede Features of the Metabolic Syndrome. <i>Journal of Clinical Rheumatology</i> , 2009, 15, 65-67.	0.9	21
82	Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2011, 7, 284-298.	0.3	21
83	Cardiovascular risk factors in patients with spondyloarthritis from Northern European and Mediterranean countries: An ancillary study of the ASAS-COMOSPA project. <i>Joint Bone Spine</i> , 2018, 85, 447-453.	1.6	21
84	Assessment of Fatigue in Spondyloarthritis and Its Association with Disease Activity. <i>Journal of Rheumatology</i> , 2016, 43, 751-757.	2.0	20
85	Molecular Characterization of Monocyte Subsets Reveals Specific and Distinctive Molecular Signatures Associated With Cardiovascular Disease in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2019, 10, 1111.	4.8	20
86	Measuring Spinal Mobility Using an Inertial Measurement Unit System: A Validation Study in Axial Spondyloarthritis. <i>Diagnostics</i> , 2020, 10, 426.	2.6	20
87	Role of microRNAs in the Development of Cardiovascular Disease in Systemic Autoimmune Disorders. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1212.	4.1	20
88	Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies. <i>Haematologica</i> , 2020, 105, 2250-2261.	3.5	20
89	Gender-Specific Effects of Genetic Variants within Th1 and Th17 Cell-Mediated Immune Response Genes on the Risk of Developing Rheumatoid Arthritis. <i>PLoS ONE</i> , 2013, 8, e72732.	2.5	20
90	An analysis of 372 patients with anterior uveitis in a large Ibero-American cohort of spondyloarthritis: the RESPONDIA Group. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 484-9.	0.8	20

#	ARTICLE	IF	CITATIONS
91	Clinical utility of the ASDAS index in comparison with BASDAI in patients with ankylosing spondylitis (Axis Study). <i>Rheumatology International</i> , 2017, 37, 1817-1823.	3.0	19
92	The potential of ESSG spondyloarthropathy classification criteria as a diagnostic aid in rheumatological practice. <i>Journal of Rheumatology</i> , 2002, 29, 326-30.	2.0	19
93	The cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in Spain. Comparison of clinical trial and clinical practice data. <i>Scandinavian Journal of Rheumatology</i> , 2008, 37, 62-71.	1.1	18
94	Infliximab Reduces Myeloperoxidase Concentration in Chronic Inflammatory Joint Diseases. <i>Pharmacology</i> , 2009, 83, 211-216.	2.2	18
95	Genetic polymorphisms inside and outside the MHC improve prediction of AS radiographic severity in addition to clinical variables. <i>Rheumatology</i> , 2012, 51, 1471-1478.	1.9	18
96	Validation of a new objective index to measure spinal mobility: the University of Cordoba Ankylosing Spondylitis Metrology Index (UCOASMI). <i>Rheumatology International</i> , 2014, 34, 401-406.	3.0	18
97	Enhanced NETosis generation in radiographic axial spondyloarthritis: utility as biomarker for disease activity and anti-TNF therapy effectiveness. <i>Journal of Biomedical Science</i> , 2020, 27, 54.	7.0	18
98	Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 56-67.	0.9	18
99	Fine mapping of a major histocompatibility complex in ankylosing spondylitis: Association of the <i>HLA*DPB1</i> and <i>HLA*DRB1</i> regions. <i>Arthritis and Rheumatism</i> , 2011, 63, 3305-3312.	6.7	17
100	Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 323-333.	1.5	17
101	Inter-rater reliability of clinical mobility measures in ankylosing spondylitis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 382.	1.9	16
102	A high density SNP genotyping approach within the 19q13 chromosome region identifies an association of a CNOT3 polymorphism with ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 714-717.	0.9	14
103	Development and Validation of a New Instrument to Measure Health-related Quality of Life in Patients with Psoriatic Arthritis: The VITACORA-19. <i>Journal of Rheumatology</i> , 2014, 41, 2008-2017.	2.0	14
104	Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 432-443.	1.5	14
105	Subclinical cardiovascular risk signs in adults with juvenile idiopathic arthritis in sustained remission. <i>Pediatric Rheumatology</i> , 2020, 18, 59.	2.1	14
106	Role of HLA-B27 in the comorbidities observed in Axial Spondyloarthritis: Data from COMOSPA. <i>Joint Bone Spine</i> , 2020, 87, 445-448.	1.6	14
107	Recomendaciones para la detección, investigación y derivación del dolor lumbar inflamatorio en Atención Primaria. <i>Reumatología Clínica</i> , 2015, 11, 90-98.	0.5	13
108	Upswings in Cheerful Mood and Disease Activity in Patients with Rheumatoid Arthritis. <i>International Journal of Behavioral Medicine</i> , 2016, 23, 606-610.	1.7	13



#	ARTICLE	IF	CITATIONS
109	Integrative Clinical, Molecular, and Computational Analysis Identify Novel Biomarkers and Differential Profiles of Anti-TNF Response in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 631662.	4.8	13
110	Assessment of the relationship between estimated cardiovascular risk and structural damage in patients with axial spondyloarthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2098283.	2.7	13
111	Decreased levels of uric acid after oral glucose challenge is associated with triacylglycerol levels and degree of insulin resistance. <i>British Journal of Nutrition</i> , 2008, 99, 44-48.	2.3	12
112	Candidateâ€™s single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in ankylosing spondylitis. <i>Rheumatology International</i> , 2014, 34, 793-801.	3.0	12
113	Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and spondyloarthritis. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232096506.	2.5	12
114	Current Controversies in Spondyloarthritis: SPARTAN. <i>Journal of Rheumatology</i> , 2010, 37, 2617-2623.	2.0	11
115	Positive and negative affective states and disease activity in ankylosing spondylitis. <i>Rheumatology International</i> , 2015, 35, 519-524.	3.0	11
116	Characterization of Antiphospholipid Syndrome Atherothrombotic Risk by Unsupervised Integrated Transcriptomic Analyses. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 865-877.	2.4	11
117	The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast. <i>Journal of Internal Medicine</i> , 2022, 291, 676-693.	6.0	11
118	Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in Spondyloarthritis except for Psoriatic Arthritis. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2011, 7, 113-123.	0.3	10
119	Usefulness of a centralized system of data collection for the development of an international multicentre registry of spondyloarthritis. <i>Rheumatology</i> , 2011, 50, 132-136.	1.9	10
120	Polymorphisms of HLAâ€A, â€B, â€Cw and DRB1 antigens in Moroccan patients with ankylosing spondylitis and a comparison of clinical features with frequencies of <i>HLAâ€B*27</i>. <i>Tissue Antigens</i> , 2015, 85, 108-116.	1.0	10
121	Real-world cost-effectiveness of infliximab, etanercept and adalimumab in rheumatoid arthritis patients: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 231-241.	3.0	10
122	Desarrollo de un cuadro de actuaciÃn para la evaluaciÃn de pacientes con espondiloartritis axial y artritis psoriÃsica en la prÃctica diaria: proyecto ONLY TOOLS. <i>ReumatologÃa ClÃnica</i> , 2018, 14, 155-159.	0.5	10
123	Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 83-96.	2.0	10
124	Modelo de excelencia en el Hospital de DÃa de ReumatologÃa en EspaÃa: proyecto HD-Reumatolex. <i>ReumatologÃa ClÃnica</i> , 2013, 9, 142-147.	0.5	9
125	Recomendaciones para la prescripciÃn de ejercicio fÃsico en pacientes con espondiloartritis. <i>ReumatologÃa ClÃnica</i> , 2019, 15, 77-83.	0.5	9
126	Mechanical Properties of Lumbar and Cervical Paravertebral Muscles in Patients with Axial Spondyloarthritis: A Case-Control Study. <i>Diagnostics</i> , 2021, 11, 1662.	2.6	9



#	ARTICLE	IF	CITATIONS
127	Both Baseline Clinical Factors and Genetic Polymorphisms Influence the Development of Severe Functional Status in Ankylosing Spondylitis. PLoS ONE, 2012, 7, e43428.	2.5	9
128	Distribution of HLA-DRB1 genes in patients with sporadic ankylosing spondylitis in the south of Spain. Joint Bone Spine, 2002, 69, 458-462.	1.6	8
129	Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis. Rheumatology, 2018, 57, 880-890.	1.9	8
130	Axial and peripheral spondyloarthritis: does psoriasis influence the clinical expression and disease burden? Data from REGISPONER registry. Rheumatology, 2021, 60, 1125-1136.	1.9	8
131	Update on the clinical pharmacology of etoricoxib, a potent cyclooxygenase-2 inhibitor. Future Rheumatology, 2007, 2, 545-565.	0.2	7
132	Association of the Intergenic Single-Nucleotide Polymorphism rs10865331 (2p15) with Ankylosing Spondylitis in a Spanish Population. Journal of Rheumatology, 2010, 37, 2345-2347.	2.0	7
133	Different Clinical Expression of Patients With Ankylosing Spondylitis According to Gender in Relation to Time Since Onset of Disease. Data From REGISPONER. Reumatología Clínica (English Edition), 2013, 9, 221-225.	0.3	7
134	Recomendaciones para el manejo de la comorbilidad en la práctica clínica en pacientes con espondiloartritis axial. Reumatología Clínica, 2018, 14, 346-359.	0.5	7
135	Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium. Scientific Reports, 2019, 9, 14812.	3.3	7
136	Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 2019, 11, 1759720X1988074.	2.7	7
137	Hip and Shoulder Involvement and Their Management in Axial Spondyloarthritis: a Current Review. Current Rheumatology Reports, 2020, 22, 53.	4.7	7
138	Distribution of comorbidities in spondyloarthritis with regard to the phenotype and psoriasis: data from the ASAS-COMOSPA study. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110452.	2.7	7
139	ASAS Health Index in patients with spondyloarthritis and its association with disease activity and disease burden including fibromyalgia. Clinical and Experimental Rheumatology, 2021, 39, 82-88.	0.8	7
140	Osteonecrosis of the tibial plateau. Clinical Rheumatology, 1998, 17, 95-98.	2.2	6
141	ICAM-1 Expression on the Surface of T Lymphocytes in Patients with Uveitis: A Comparative Study between the Eye and Peripheral Blood. Ophthalmologica, 2002, 216, 203-208.	1.9	6
142	Nuevos paradigmas en el diagnóstico y la clasificación de las espondiloartritis. Reumatología Clínica, 2013, 9, 199-200.	0.5	6
143	Comparación de 2 estrategias de derivación en el diagnóstico de la espondiloartritis axial en España. Estudio RADAR. Reumatología Clínica, 2013, 9, 348-352.	0.5	6
144	High Reproducibility of an Automated Measurement of Mobility for Patients with Axial Spondyloarthritis. Journal of Rheumatology, 2018, 45, 1383-1388.	2.0	6

#	ARTICLE	IF	CITATIONS
145	Remission in axial spondyloarthritis: Developing a consensus definition. <i>Reumatología Clínica</i> , 2021, 17, 380-387.	0.5	6
146	Sustained low disease activity measured by ASDAS slow radiographic spinal progression in axial spondyloarthritis patients treated with TNF-inhibitors: data from REGISPONSERBIO. <i>Arthritis Research and Therapy</i> , 2022, 24, 30.	3.5	6
147	Ankylosing Spondylitis without Axial Progression: Analysis of Associated Factors. <i>Journal of Rheumatology</i> , 2014, 41, 2409-2412.	2.0	5
148	Recommendations for the Detection, Study and Referral of Inflammatory Low-back Pain in Primary Care. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 90-98.	0.3	5
149	Cost-effectiveness of clinical remission by treat to target strategy in established rheumatoid arthritis: results of the CREATE registry. <i>Rheumatology International</i> , 2016, 36, 1627-1632.	3.0	5
150	Quantification of Joint Laxity. "The Non-Dominant(Spanish) Modification"™. <i>Rheumatology</i> , 1995, 34, 795-796.	1.9	4
151	Atlas of axial spondyloarthritis in Spain 2017: Study design and population. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 127-132.	0.3	4
152	Consenso ASAS en nomenclatura en español para las espondiloartritis. <i>Reumatología Clínica</i> , 2020, 16, 333-338.	0.5	4
153	Does Belonging to a Patient Association Is of Help for Patients with Axial Spondyloarthritis? Results from the Atlas Survey. <i>Current Rheumatology Reports</i> , 2020, 22, 22.	4.7	4
154	Molecular Changes in the Adipose Tissue Induced by Rheumatoid Arthritis: Effects of Disease-Modifying Anti-Rheumatic Drugs. <i>Frontiers in Immunology</i> , 2021, 12, 744022.	4.8	4
155	Fast detection of marker pixels in video-based motion capture systems. <i>Pattern Recognition Letters</i> , 2009, 30, 432-439.	4.2	3
156	Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe. <i>Rheumatology</i> , 2021, 60, 113-124.	1.9	3
157	Which factors explain the patient global assessment in patients with ankylosing spondylitis? A hierarchical cluster analysis on REGISPONSER-AS. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 875-879.	3.4	3
158	Subclinical Atherosclerosis Measure by Carotid Ultrasound and Inflammatory Activity in Patients with Rheumatoid Arthritis and Spondylarthritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 662.	2.4	3
159	Chondrocalcinosis and Hypomagnesemia: Clinical and Radiological Progression. <i>Reumatología Clínica (English Edition)</i> , 2008, 4, 37-39.	0.3	2
160	THU0398...Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients. Preliminary Results of a Clinical Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 340.3-341.	0.9	2
161	Optimization of biological therapy in rheumatoid arthritis patients: outcomes from the CREATE registry after 2 years of follow-up. <i>Rheumatology International</i> , 2017, 37, 1701-1708.	3.0	2
162	Development of a Checklist for Patients With Axial Spondyloarthritis and Psoriatic Arthritis in Daily Practice: ONLY TOOLS Project. <i>Reumatología Clínica (English Edition)</i> , 2018, 14, 155-159.	0.3	2

#	ARTICLE	IF	CITATIONS
163	Recommendations for the Prescription of Physical Exercise for Patients With Spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 77-83.	0.3	2
164	Assessment of SpondyloArthritis International Society (ASAS) consensus on Spanish nomenclature for spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 333-338.	0.3	2
165	Patients with Axial Spondyloarthritis Show an Altered Flexion/Relaxation Phenomenon. <i>Diagnostics</i> , 2021, 11, 810.	2.6	2
166	Uveitis as the first symptom in spondyloarthritis and its association with the evolution of the disease. Results from the REGISPONSER registry. <i>Joint Bone Spine</i> , 2021, 88, 105136.	1.6	2
167	A Benchmarking Study Evaluating Axial Spondyloarthritis Burden in Spain and Other European Countries. Results from the Spanish Atlas and the European Map of Axial Spondyloarthritis (EMAS) Studies. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1127-1136.	1.9	2
168	Expression of DDX11 and DNMI1L at the 12p11 Locus Modulates Systemic Lupus Erythematosus Susceptibility. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7624.	4.1	2
169	Genetic Polymorphisms of GGH and ABCC2 Are Associated with Methotrexate Intolerance in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4070.	2.4	2
170	Understanding the Disease Burden of Unemployed Patients With Axial Spondyloarthritis: Results From the Spanish Atlas 2017. <i>Journal of Rheumatology</i> , 2022, 49, 373-379.	2.0	2
171	New Paradigms in the Diagnosis and Classification of the Spondylarthritis. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 199-200.	0.3	1
172	Recent updates on the recommendations for the management of ankylosing spondylitis: what and why?. <i>International Journal of Clinical Rheumatology</i> , 2013, 8, 361-371.	0.3	1
173	ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy. <i>Reumatología Clínica (English Edition)</i> , 2014, 10, 204-209.	0.3	1
174	OP0188â€¦Circulating Mirnas as Potential Biomarkers of Therapy Effectiveness in Rheumatoid Arthritis Patients Treated with Anti-TNF. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 133.3-134.	0.9	1
175	Nonradiographic axial spondyloarthritis. What brings the new concept?. <i>Clinical Rheumatology</i> , 2015, 34, 195-197.	2.2	1
176	AB0694â€¦Inertial Sensor for The Assessment of Cervical Range of Movement in Axial Spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1141.4-1142.	0.9	1
177	THU0624â€¦Assessment of psychic experiences in patients with rheumatic diseases. , 2017, , .		1
178	AB0867â€¦Axial spondyloarthritis posture assessment using inertial sensors. , 2018, , .		1
179	Similarities and differences between non-radiographic and radiographic axial spondyloarthritis: The patient perspective from the Spanish atlas. <i>Reumatología Clínica</i> , 2020, , .	0.5	1
180	O31â€¦Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. , 2020, , .		1

#	ARTICLE	IF	CITATIONS
181	Prevalence and Associated Factors of Low Bone Mineral Density in the Femoral Neck and Total Hip in Axial Spondyloarthritis: Data from the CASTRO Cohort. <i>Journal of Clinical Medicine</i> , 2021, 10, 2664.	2.4	1
182	Potential Role and Impact of Peripheral Blood Mononuclear Cells in Radiographic Axial Spondyloarthritis-Associated Endothelial Dysfunction. <i>Diagnostics</i> , 2021, 11, 1037.	2.6	1
183	Future Challenges and Critical Approach to Metrology in Patients with Axial Spondyloarthritis. <i>Diagnostics</i> , 2021, 11, 1533.	2.6	1
184	Remission in axial spondyloarthritis: Developing a consensus definition. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 380-387.	0.3	1
185	Assessment of Subclinical Psychotic Symptoms in Patients with Rheumatoid Arthritis and Spondyloarthritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3461.	2.4	1
186	Impact of the number of comorbidities on the outcome measures and on the retention rate of the first anti-TNF in patients with Ankylosing Spondylitis. Two-year follow-up in REGISPONSER-AS. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151938.	3.4	1
187	Association between Carotid Intima-Media Thickness and the Use of Biological or Small Molecule Therapies in Patients with Rheumatoid Arthritis. <i>Diagnostics</i> , 2022, 12, 64.	2.6	1
188	Distribution du gène HLA-DRB1 dans une population de patients atteints de spondylarthrite ankylosante sporadique du sud de l'Espagne. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2002, 69, 886-891.	0.0	0
189	Digital Densitometry for Evaluation of Osteoporosis in Spondyloarthropathy Patients. <i>Journal of Clinical Rheumatology</i> , 2007, 13, 111-112.	0.9	0
190	L'association au thotrexate améliore l'efficacité de l'infliximab dans la spondylarthrite ankylosante. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2007, 74, 470-474.	0.0	0
191	Ankylosing spondylitis and other spondyloarthropathies: extra-articular manifestations and their management. <i>Future Rheumatology</i> , 2008, 3, 457-473.	0.2	0
192	311 INFLAMMATION, LEUKOCYTE ACTIVATION, AND SURROGATE ATHEROSCLEROSIS MARKERS IN RHEUMATOID ARTHRITIS PATIENTS ARE RELATED TO MITOCHONDRIAL DEPOLARISATION AND OXIDATIVE STRESS. <i>Atherosclerosis Supplements</i> , 2011, 12, 67.	1.2	0
193	414 OXIDATIVE STRESS MEDIATES APL-INDUCED THROMBOSIS AND ATHEROSCLEROSIS DEVELOPMENT IN ANTIPHOSPHOLIPID SYNDROME. <i>Atherosclerosis Supplements</i> , 2011, 12, 89.	1.2	0
194	SAT0044...Anti-cyclic citrullinated protein antibodies induce inflammation and oxidative stress in monocytes and neutrophils of rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 485.3-485.	0.9	0
195	SAT0161...Fluvastatin treatment prevents the inflammatory/oxidative status linked to the clinical activity of the disease in systemic lupus erythematosus patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 526.2-526.	0.9	0
196	THU0411...Utility of ultrasound scores in assessment enthesitis on anti-TNF therapy of spondyloarthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 294.1-294.	0.9	0
197	AB0733...Which Chronic Back Pain (CBP) Characteristics Are Associated with A Positive HLA-B27 in Patients with Suspected Axial Spondyloarthritis (AXSPA)? Results from the Esperanza Cohort: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1045.2-1046.	0.9	0
198	AB0188...Atherosclerosis and Cardiovascular Disease in Systemic Lupus Erythematosus. Effects of Statins Treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 865.2-865.	0.9	0

#	ARTICLE	IF	CITATIONS
199	SAT0420â€¦Ground Reaction Forces in Patients with Knee Osteoarthritis after Intra-Articular Treatments: Annals of the Rheumatic Diseases, 2014, 73, 746.3-747.	0.9	0
200	AB0164â€¦Analysis of Jak-Stat-Socs Signal Pathway mRNA Expression in Ankylosing Spondylitis (AS) Patients with Peripheral Arthritis (PA). Annals of the Rheumatic Diseases, 2014, 73, 857.1-857.	0.9	0
201	FRI0129â€¦Similarities and Differences between Axial and Peripheral Predominant Forms in Patients with Early Spondyloarthritis: Results from the Esperanza Cohort: Annals of the Rheumatic Diseases, 2014, 73, 428.2-429.	0.9	0
202	AB0133â€¦Role of Monocytes Subsets in the Atherothrombosis and Endothelial Dysfunction Associated with Rheumatoid Arthritis: Beneficial Effects of Tocilizumab. Annals of the Rheumatic Diseases, 2015, 74, 935.2-935.	0.9	0
203	FRI0190â€¦Role of Leukocyte Subsets in the Inflammation, Oxidative Stress and Bone Turnover in Ankylosing Spondylitis Patients. Annals of the Rheumatic Diseases, 2015, 74, 493.2-493.	0.9	0
204	FRI0218â€¦Structural Damage Distribution at Vertebral Level in Patients with Axial Spondyloarthritis. Annals of the Rheumatic Diseases, 2015, 74, 503.2-504.	0.9	0
205	AB0165â€¦Regulation of Atherothrombosis in Systemic Lupus Erythematosus. Role of Different Monocyte Subsets, Netosis Involvement, and Effects of Anti-Dsdna Antibodies. Annals of the Rheumatic Diseases, 2015, 74, 945.3-946.	0.9	0
206	AB0134â€¦Role of Macrophages in the Cardiovascular Disease Associated to Rheumatoid Arthritis: Effects of Anti-CCPS in the Phenotypic Switching and the Insulin Signalling. Annals of the Rheumatic Diseases, 2015, 74, 935.3-936.	0.9	0
207	OPO156â€¦In Vitro Treatment with Anti-Cardiolipin and Anti-DSDNA Antibodies Modifies the Expression of Micrnas Related to Cardiovascular Disease in Patients with Antiphospholipid Syndrome and Systemic Lupus Erythematosus. Annals of the Rheumatic Diseases, 2015, 74, 128.1-128.	0.9	0
208	THU0243â€¦Integrated Analysis of Microna and mRNA Expression Profiles Related To Cardiovascular Disease in Monocytes from Systemic Lupus Erythematosus Patients. Annals of the Rheumatic Diseases, 2016, 75, 276.1-276.	0.9	0
209	THU0254â€¦In Vivo Ubiquinol (COQ10) Supplementation Reduces The Atherothrombotic Status of Antiphospholipid Syndrome Patients. Annals of the Rheumatic Diseases, 2016, 75, 280.1-280.	0.9	0
210	OPO310â€¦Association of Neutrophil Extracellular Traps with Atherosclerosis in Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2016, 75, 175.1-175.	0.9	0
211	AB0104â€¦Role of CD14+ and CD16+ Monocyte Subtypes in The Atherothrombosis Associated with Rheumatoid Arthritis: Epigenetic Mechanisms Involved. Annals of the Rheumatic Diseases, 2016, 75, 932.1-932.	0.9	0
212	FRI0046â€¦TCZ Attenuates Atherothrombosis through The Specific Inhibition of Netosis and Monocyte-Mediated Proinflammatory Activity. Annals of the Rheumatic Diseases, 2016, 75, 442.3-443.	0.9	0
213	FRI0056â€¦Altered Microna Expression Pattern in Synovial and Blood Neutrophils in Rheumatoid Arthritis Reveals The Pathogenic Profile of These Cells. Annals of the Rheumatic Diseases, 2016, 75, 446.1-446.	0.9	0
214	AB0116â€¦Induction of Netosis-Mediated Cell Death in Ankylosing Spondylitis Patients. Annals of the Rheumatic Diseases, 2016, 75, 936.2-936.	0.9	0
215	AB0124â€¦Peripheral Blood Mononuclear Cells from Ankylosing Spondylitis Patients Display An Atherogenic Profile Associated with Disease Activity and Endothelial Dysfunction. Annals of the Rheumatic Diseases, 2016, 75, 939.1-939.	0.9	0
216	THU0255â€¦Identification of Novel Regulatory Networks Related To Atherothrombosis in Monocytes from Antiphospholipid Syndrome through Integrated Analysis of Microna/mrna/protein Expression Profiles. Annals of the Rheumatic Diseases, 2016, 75, 280.2-280.	0.9	0

#	ARTICLE	IF	CITATIONS
217	THU0400â€...Relationship between Health Quality of Life and Other Indicators in Patients with Axial Spondyloarthritis: Table 1. Annals of the Rheumatic Diseases, 2016, 75, 333.1-333.	0.9	0
218	FRI0394â€...Assessment of Cardiovascular Risk Factors in Patients with Spondyloarthritis and Their Association with Disease Features and Its Activity. A Comparison between Two Population Groups from Asas-Comospa. Annals of the Rheumatic Diseases, 2016, 75, 577.2-578.	0.9	0
219	FRI0429â€...Dysregulation of the splicing machinery in leukocytes from ankylosing spondylitis patients is associated to disease pathogenesis. , 2017, , .		0
220	OPO238â€...Measurement of spinal mobility in axial spondyloarthritis using inertial sensors: reliability and validation preliminary results. , 2017, , .		0
221	AB0127â€...ANTI-DS-DNA antibodies regulate atherothrombosis in systemic lupus erythematosus through the induction of netosis, inflammation and endothelial activation. , 2017, , .		0
222	THU0218â€...Circulating micrnas as biomarkers for diagnosis and typifying the atherothrombotic status in antiphospholipid syndrome. , 2017, , .		0
223	PARE0020â€...25 years of patients' associations of ankylosing spondylitis in spain: aceade. , 2017, , .		0
224	FRI0048â€...The ANTI-CD20 antibody rituximab reduces the inflammatory and prothrombotic profile of leukocytes from rheumatoid arthritis patients and modulates the activity of endothelial cells. , 2017, , .		0
225	FRI0452â€...Impact of a training program and early referral on diagnostic delay in patients with axial spondyloarthritis: results from the spanish atlas. , 2017, , .		0
226	THU0380â€...Results of a real life dose-reduction strategy for anti-tnfalpa inhibitors in a cohort of patients with spondyloarthritis. , 2017, , .		0
227	FRI0360â€...Analysis of endocannabinoid system elements and related inflammatory molecules in peripheral blood leukocytes of patients with systemic sclerosis. , 2017, , .		0
228	AB0619â€...Connective tissue disease-associated interstitial lung disease treated with cyclophosphamide or rituximab: a unicentre, open-label and comparative study. , 2017, , .		0
229	FRI0434â€...Poor quality of life in patients with spondyloarthritis is not explained by structural damage. data from regisponser. , 2017, , .		0
230	SAT0412â€...Association between smoking with spinal level of stiffness and functional limitation in patients with axial spondyloarthritis: results from the spanish atlas. , 2017, , .		0
231	SAT0391â€...Lumbar flexion/relaxation phenomenon in patients with axial spondyloarthritis. , 2017, , .		0
232	SAT0447â€...Prevalence of radiographic sacroiliitis in patients with psoriatic arthritis and the clinical, analytical and demographic factors associated to its appearance. , 2017, , .		0
233	FRI0431â€...Altered expression of circulating micrnas is related to disease activity and structural damage in ankylosing spondylitis patients. , 2017, , .		0
234	AB0353â€...Genetically predisposition and pro-inflammatory dysregulations â€“ connecting rheumatoid arthritis and mental disorders. , 2018, , .		0



#	ARTICLE	IF	CITATIONS
235	SAT0331â€...Inflammatory markers and adipokines related to cardiovascular risk and metabolic comorbidities in psoriatic arthritis. in vivo effects of apremilast. , 2018, , .		0
236	AB0698â€...EFFECTIVENESS AND SAFETY OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF AXIAL SPONDYLOARTHRITIS IN REAL-WORLD CLINICAL PRACTICE IN EUROPE: RESULTS FROM A PROSPECTIVE NON-INTERVENTIONAL 12-MONTH COHORT STUDY. , 2019, , .		0
237	AB0734Câ€...REMISSION IN AXIAL SPONDYLOARTHRITIS: A DELPHI-METHOD QUESTIONNAIRE AMONG EXPERTS TO EVALUATE THE AVAILABLE ASSESSMENT TOOLS TO MEASURE DISEASE ACTIVITY AND TO DEVELOP A CONSENSUS DEFINITION OF REMISSION. , 2019, , .		0
238	AB0725â€...ASSOCIATION BETWEEN RADIOGRAPHIC PROGRESSION AND CARDIOVASCULAR RISK IN SPONDYLOARTHRITIS: DATA FROM COSPAR REGISTRY. , 2019, , .		0
239	Facteurs de risque cardiovasculaire chez des patients atteints de spondyloarthrite originaires du nord de lâ€™Europe et des pays mÃ©diterranÃ©ens: une Ã©tude dÃ©rivÃ©e du projet Asas-Comospa. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 63-69.		0
240	FRI0215â€...Asas consensus on spanish nomenclature for spondyloarthritis. , 2018, , .		0
241	THU0297â€...Evaluation of cardiovascular risk factors among patients with psoriasis, psoriatic arthritis and peripheral spondyloarthritis. , 2018, , .		0
242	THU0076â€...Antibodies to citrullinated protein antigens (ACPAS) induce adipose tissue dysfunction impairing adipocyte differentiation, lipid accumulation and promoting macrophage polarisation. in vitro effect of biologic dmards. , 2018, , .		0
243	AB0394â€...Observational study of the incidence of cardiovascular events and associated comorbidities in a cohort of patients with recent onset rheumatoid arthritis. , 2018, , .		0
244	THU0576â€...Cardiovascular risk in long-term juvenile idiopathic arthritis. , 2018, , .		0
245	Similarities and differences between non-radiographic and radiographic axial spondyloarthritis: The patient perspective from the Spanish atlas. ReumatologÃa ClÃnica (English Edition), 2022, 18, 169-176.	0.3	0